The company has transitioned from primarily designing and manufacturing medical syringes to a medical device sales and distribution enterprise, alongside a new digital asset treasury strategy. A digital asset treasury strategy was adopted on August 23, 2025, focusing on accumulating Solana (SOL), which now constitutes the principal holding in its treasury reserve. A Private Investment in Public Equity (PIPE) offering closed on August 28, 2025, raising approximately $400 million, which was primarily used to purchase over 2,000,000 SOL. The company reported a significant net loss of $282.5 million for the fiscal year ended December 31, 2025, compared to a net loss of $9.3 million in 2024. Key drivers for the 2025 net loss included $107.5 million in stock compensation charges, $152.9 million in unrealized losses on digital assets, and asset impairments. As of December 31, 2025, the fair value of digital assets held was $250.1 million, with an average cost basis of approximately $198 per SOL, declining to a market value of $124 per SOL. Net staking revenue from SOL holdings amounted to $6.8 million in 2025, with approximately 95% of SOL holdings staked. A share repurchase program of up to $100 million was approved on October 2, 2025, leading to the repurchase of 867,678 shares for $1.57 million (excluding fees) between January and March 2026. Outstanding litigation was settled on October 6, 2025, resulting in the spinoff of the Hungarian subsidiary, Safegard Medical Kft. The company underwent reverse stock splits in April 2025 (1-for-300) and October 2024 (1-for-22).